PepPalPepPal
    Back to Knowledge Base

    Tesamorelin

    Growth Hormone

    Tesamorelin Acetate

    PepPal is a research assistant. All information is provided for educational and research purposes only and is not medical advice. Peptides discussed are not approved for human consumption unless prescribed by a licensed medical professional.

    Overview

    Tesamorelin is a stabilised synthetic analogue of Growth Hormone Releasing Hormone (GHRH). It is the only FDA-approved peptide for visceral fat reduction (brand name Egrifta), with robust clinical trial evidence. It triggers the pituitary's own pulsatile GH secretion for a natural hormonal rhythm.

    Mechanism of Action

    Tesamorelin binds to GHRH receptors, stimulating the synthesis and release of endogenous growth hormone from the pituitary while maintaining the physiological pulsatile pattern of GH secretion.

    Research Contexts

    Visceral fat reduction • IGF-1 elevation • Cognitive function • Lipid profile improvement • Body composition • Sleep quality

    Dosing (PepPal Protocol)

    PepPal only publishes dosing from our vetted protocol PDFs. For peptides without an official PepPal protocol, see the Protocols page.

    Step 1: 1 mg daily for 2 weeks (20 units). Step 2: 2 mg daily ongoing (40 units). Once daily subcutaneous, evening/pre-sleep, fasted. 12–16 weeks on / 4 weeks off.

    Reconstitution Guide

    Vial size: 5 mg or 10 mg Water volume: 1 mL per 5 mg (5 mg vial = 1 mL, 10 mg vial = 2 mL) Concentration: 0.05 mg per unit (both vial sizes identical concentration) Draw up slowly along the vial wall — do not shake. 1 mg dose = 20 units, 2 mg dose = 40 units. Inject at least 1 hour before eating or 1.5–2 hours after last meal. Pre-sleep on empty stomach is optimal.

    Storage Guidelines

    Before reconstitution: Refrigerate at 2–8°C. Do not freeze. After reconstitution: Refrigerate at 2–8°C. Use within 3–4 weeks.

    Half-Life & Stability

    Half-life: 26–38 minutes Stability: Less stable than some peptides; use promptly after reconstitution. Visceral fat results are most pronounced between weeks 8–16.